Renal Cell Carcinoma

Journal Updates
Tivozanib Prolongs PFS in Refractory Kidney Cancer
eMediNexus, 22 December 2019
#Internal Medicine #Nephrology #Oncology #Pathology and Lab Medicine #Pharmacist

In patients with refractory renal cell carcinoma (RCC), third- or fourth-line tivozanib improved progression-free survival and w ...MORE

649 Views
0 Comments

Clinical News
Pembrolizumab + axitinib improves overall survival and progression-free survival in metastatic renal cell carcinoma
eMediNexus, 14 February 2019
#Hematology #Nephrology #Oncology #Pathology and Lab Medicine #Pharmacist

Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of the PD-1 ta ...MORE

862 Views
1 Comments

Journal Updates
Older adults undergoing dialysis at risk of dementia
eMediNexus, 11 August 2018
#Internal Medicine #Nephrology #Neurology #Psychiatry

Older adults who initiate dialysis for kidney failure are at a greater risk of being diagnosed with dementia and Alzheimer’s disease. Age ≥86 years, ...MORE

948 Views
0 Comments

Journal Updates
Sunitinib alone not inferior to nephrectomy with sunitinib in metastatic renal-cell carcinoma
eMediNexus, 04 August 2018
#Hematology #Nephrology #Oncology #Pharmacist

Sunitinib alone was not inferior to nephrectomy followed by sunitinib in patients with metastatic clear-cell renal-cell carcinoma who were classified as havi ...MORE

1016 Views
0 Comments

Journal Updates
Targeted therapy with sunitinib as good as surgery in metastatic renal cell carcinoma
eMediNexus, 06 June 2018
#General Surgery #Nephrology #Oncology

Treatment with sunitinib alone was not inferior to cytoreductive nephrectomy followed by sunitinib in patients with metastatic renal cell carcinoma who were ...MORE

947 Views
0 Comments

Clinical News
Adding immunotherapy to standard treatment slows advanced kidney cancer progression
eMediNexus, 08 February 2018
#Nephrology #Oncology #Pathology and Lab Medicine #Radiology

Patients with previously untreated metastatic renal cell cancer (mRCC), combining immunotherapy atezolizumab with targeted therapy bevacizumab delayed cancer ...MORE

1244 Views
3 Comments
Prev123Next